

**Aashka Hospitals Ltd.**

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421. Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
[www.aashkahospitals.in](http://www.aashkahospitals.in)  
CIN: L85110GJ2012PLC072647



October 30, 2024

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001

**Script Code:** 543346

Dear Sir / Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Board Meeting Outcome**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“**LODR Regulations**”), the meeting of Board of Directors of the Company held today i.e. October 30, 2024 at 14:00 hours and concluded at 15:10 Hours, and has *inter alia* considered and approved the following matters:

- 1) Unaudited Financial Result for the Half Year ended on September 30, 2024, as recommended by the Audit Committee
- 2) Appointment of Mr. Jigar Kanakchandra Trivedi (DIN: 10548094), as an Additional Independent Director for the Term of 5 (five) years w.e.f. November 1, 2024. Further the details required under Regulation 30 of the LODR Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in Annexure – I.

We request you to take this intimation on your records.

Thanking you,  
Yours faithfully,

**For, Aashka Hospitals Limited**

**Bipinchandra D. Shah**  
**Chairman & Managing Director**  
**DIN: 009348108**

Encl.: a/a

**Aashka Hospitals Ltd.**

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421. Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
[www.aashkahospitals.in](http://www.aashkahospitals.in)  
CIN: L85110GJ2012PLC072647

**ANNEXURE – I****Appointment of Mr. Jigar Kanakchandra Trivedi (DIN: 10548094) as on Additional Independent Director**

<b>Reason for Change viz. Appointment, Resignation, Removal, Death or otherwise</b>	Appointment as Additional Director of the Company, in the category of Non – Executive – Independent Director
<b>Date of Appointment / Cessation</b>	November 1, 2024
<b>Terms of Appointment</b>	From November 1, 2024 upto October 30, 2029 (both days inclusive), subject to the approval of the Shareholders at the General Meeting
<b>Brief Profile</b>	<p>Mr. Jigar Kanakchandra Trivedi is resident of Ahmedabad and 33 Years of Age.</p> <p>He has done Bachelor of Commerce (B. Com) from Gujarat University. In 2018, he furthered his education by obtaining a Bachelor of Law degree</p> <p>He is a member of Institute of Company Secretaries of India (ICSI) and currently practices as a company secretary at his own firm, Jigar Trivedi &amp; Co.</p> <p>He has vast experience in Corporate Laws &amp; allied laws and Finance</p>
<b>Disclosure of Relationships between Directors</b>	None
<b>Declaration</b>	In accordance with SEBI instructions to Stock Exchanges dated June 14, 2018, we confirm that Mr. Jigar Kanakchandra Trivedi is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority



**PARIMAL S. SHAH & Co.**

**Chartered Accountants**

E-mail : parimal\_vidhi@yahoo.com

B-104-105, Anand Chambers,  
Nr. Old High Court Underbridge,  
Opp. Muktajivan Photo,  
Navrangpura, Ahmedabad-380009.  
Phone : (079) 26460442, (M) 8980814999

### Limited Review Report

To,  
The Board of Directors,  
**AASHKA HOSPITALS LIMITED**

We have reviewed the accompanying statement of unaudited standalone financial results of **AASHKA HOSPITALS LIMITED** (the "Company") for the Half Year ended on September 30, 2024 (the "statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 30-10-2024  
UDIN:24038507BJZWRU6772



For, Parimal S Shah & Co.  
Chartered Accountant  
FRN: 107591W

(Parimal S Shah)  
PROPRIETOR  
M NO: 038507

## AASHKA HOSPITALS LIMITED

Reg. Off.: Between Sargasan & Reliance Cross Roads, Sargasan, Gandhinagar - 382421, Gujarat, India

CIN: L85110GJ2012PLC072647 | E-mail: cs@aashkahospitals.in | Web: www.aashkahospitals.in

Statement of Standalone Audited Financial Results for the Half Year ended on September 30, 2024

(INR in Lakhs except for EPS)

Sr. No.	Particulars	Half Year Ended			Year Ended
		30-09-2024	31-03-2024	30-09-2023	31-03-2024
		(unaudited)	(unaudited)	(unaudited)	(Audited)
<b>1</b>	<b>Income from Operations</b>				
	(a) Net Income from Operation	1,236.43	1,207.19	1,080.20	2,287.39
	(b) Other Income	6.74	160.67	260.89	421.56
	<b>Total Income from Operations (1)</b>	<b>1,243.17</b>	<b>1,367.86</b>	<b>1,341.09</b>	<b>2,708.95</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	121.85	139.80	133.94	273.74
	(c) Direct Expense	-	-	-	-
	(d) Changes in inventories of finished goods, work-in-progress and stock in trade	(8.45)	1.42	1.22	2.64
	(e) Employee benefits expense	181.31	177.85	169.82	347.67
	(f) Finance Costs	102.31	145.28	145.87	291.15
	(g) Depreciation & Amortisation Expense	157.99	145.14	146.67	291.81
	(h) Other Expenses	493.87	524.99	692.34	1,217.32
	<b>Total Expenses (2)</b>	<b>1,048.88</b>	<b>1,134.48</b>	<b>1,289.86</b>	<b>2,424.33</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional &amp; Extraordinary Items &amp; Tax (1-2)</b>	<b>194.28</b>	<b>233.38</b>	<b>51.23</b>	<b>284.62</b>
<b>4</b>	Exceptional Items	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before Extraordinary Items &amp; Tax (3-4)</b>	<b>194.28</b>	<b>233.38</b>	<b>51.23</b>	<b>284.62</b>
<b>6</b>	Extraordinary Items	-	-	-	-
<b>7</b>	<b>Profit / (Loss) before Tax (5-6)</b>	<b>194.28</b>	<b>233.38</b>	<b>51.23</b>	<b>284.62</b>
<b>8</b>	Tax Expenses - MAT	32.43	40.05	8.78	48.84
<b>9</b>	Less: MAT Credit Entitlement	-	-	-	-
<b>10</b>	<b>Profit / (Loss) after Tax (7-8+9)</b>	<b>161.85</b>	<b>193.33</b>	<b>42.45</b>	<b>235.78</b>
<b>11</b>	Paid-up Equity Share Capital (face value of INR 10/- each)	233.68	233.68	233.68	233.68
<b>12</b>	Reserve & Surpluses (Excluding Revaluation Reserve)	7,452.49	7,290.64	7,097.30	7,290.64
<b>13</b>	<b>Earning per Share</b>				
	1) Basic	0.69	0.83	0.18	1.01
	2) Diluted	0.69	0.83	0.18	1.01

**Notes:**

- 1 The above results were reviewed by Audit Committee and were approved and taken on record by Board of Directors at their meeting held on October 30, 2024
- 2 The figures of the previous period have been regrouped / rearranged where-ever necessary, to make them comparable with those of the current period
- 3 Figures for the half year ended March 31, 2024 are the balancing figures in respect to the full Financial Year and the published year to date figures up to the First Half Year ended on September 30, 2023 of the respective Financial Year which were subject to the limited review
- 4 The above financial results are available on the website of the Company i.e. www.aashkahospitals.in and on the website of BSE Limited (SME Platform) i.e. www.bseindia.com
- 5 EPS is calculated as per Accounting Standard 20 considering the split up of Equity Shares and accordingly EPS is adjusted for all the comparative periods presented
- 6 The Company does not have more than one reportable segment in terms of AS - 17 (Segment Reporting). Hence, segment wise reporting is not applicable

For, Aashka Hospitals Limited

**Bipinchandra D. Shah**  
Chairman & Managing Director  
DIN: 00934108

**Date:** October 30, 2024  
**Place:** Gandhinagar

# AASHKA HOSPITALS LIMITED

Reg. Off.: Between Sargasan & Reliance Cross Roads, Sargasan, Gandhingar - 382421, Gujarat, India  
CIN: L85110GJ2012PLC072647 | E-mail: cs@aashkahospitals.in | Web: www.aashkahospitals.in

## Statement of Standalone Assets & Liabilities for the Half Year ended on September 30, 2024

(in INR Lakhs)

Sr. No.	Particulars	30-09-2024	31-03-2024
		Unaudited	Audited
<b>A</b>	<b>EQUITY &amp; LIABILITIES</b>		
<b>1</b>	<b>Shareholder's Funds</b>		
	(a) Share Capital	2,336.80	2,336.80
	(b) Reserves and Surplus	7,452.49	7,290.64
	(c) Money received against Share Warrants	-	-
	<b>Shareholder's Funds</b>	<b>9,789.29</b>	<b>9,627.44</b>
<b>2</b>	<b>Share application money pending allotment</b>	-	-
<b>3</b>	<b>Non - Current Liabilities</b>		
	(a) Long-term Borrowings	1,116.00	826.73
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	50.40	50.40
	(d) Long-term provisions	19.95	17.86
	<b>Non - Current Liabilities</b>	<b>1,186.36</b>	<b>895.00</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	618.46	1,212.04
	(b) Trade Payables		
	(i) Total outstanding dues of Micro & Small Enterprises	-	58.99
	(ii) Total outstanding dues other than Micro & Small Enterprises	137.49	140.61
	(c) Other current liabilities	138.69	48.09
	(d) Short-term provisions	132.28	163.18
	<b>Current Liabilities</b>	<b>1,026.91</b>	<b>1,622.91</b>
	<b>TOTAL - EQUITY &amp; LIABILITIES (A)</b>	<b>12,002.56</b>	<b>12,145.35</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non - Current Assets</b>		
	(a) Fixed Assets	4,256.79	4,323.43
	(b) Non - Current Investments	-	-
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	-	-
	(e) Other non - current assets	6,518.17	6,773.30
	<b>Non - Current Assets</b>	<b>10,774.96</b>	<b>11,096.72</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	-	-
	(b) Inventories	45.83	37.38
	(c) Trade Receivables	682.24	482.19
	(d) Cash & Cash Equivalents	71.25	198.14
	(e) Short-term loans and advances	111.98	49.15
	(f) Other Current Assets	316.29	281.76
	<b>Current Assets</b>	<b>1,227.60</b>	<b>1,048.62</b>
	<b>TOTAL - ASSETS (B)</b>	<b>12,002.56</b>	<b>12,145.35</b>

For, Aashka Hospitals Limited

**Bipinchandra D. Shah**  
Chairman & Managing Director  
DIN: 00934108

**Date:** October 30, 2024  
**Place:** Gandhinagar

## AASHKA HOSPITALS LIMITED

**Reg. Off.:** Between Sargasan & Reliance Cross Roads, Sargasan, Gandhingar - 382421, Gujarat, India  
**CIN:** L85110GJ2012PLC072647 | **E-mail:** cs@aashkahospitals.in | **Web:** www.aashkahospitals.in

### Cash Flow Statement for the Half Year ended on September 30, 2024

(in INR Lakhs)

Sr. No.	Particulars	30-09-2024	31-03-2024
		Unaudited	Audited
<b>A</b>	<b>Cash Flows from used in Operating Activities</b>		
	Profit before Extraordinary items and tax	194.28	284.62
	<b>Adjustments for reconcile Profit / (Loss)</b>		
	Adjustments for finance costs	102.31	291.15
	Adjustments for deperciation and amortisation expense	157.99	291.81
	Share application money pending allotment	-	-
	Adjustments for unrealised foreign exchange losses gains	-	-
	Adjustments for dividend income	-	-
	Other adjustments for which cash effects are investing or	-	-
	Other adjustments to reconcile profit / (loss)	(4.74)	(408.37)
	Other adjustments for non-cash items	-	-
	Share of Profit & Loss from Partnership firm or association of persons or Limited Liability Partnership	-	-
	<b>Total Adjustments to Profit / (Loss)</b>	<b>255.55</b>	<b>174.59</b>
	<b>Adjustments for Working Capital</b>		
	Adjustments for decrease / (increase) in inventories	(8.45)	2.64
	Adjustments for decrease / (increase) in trade receivables	(200.05)	203.50
	Adjustments for decrease / (increase) in other non current assets	255.12	79.13
	Adjustments for decrease / (increase) in Loans & Advances	(62.83)	8.26
	Adjustments for decrease / (increase) in other current assets	(34.52)	28.15
	Adjustments for increase / (decrease) in trade payables	(62.12)	(58.46)
	Adjustments for increase / (decrease) in other non current liabilities	-	-
	Adjustments for increase / (decrease) in other current liabilities	59.69	46.56
	Adjustments for provisions	2.09	(2.44)
	<b>Total Adjustments for Working Capital</b>	<b>(51.06)</b>	<b>307.34</b>
	<b>Total Adjustments to reconcile Profit / (Loss)</b>	<b>204.49</b>	<b>481.93</b>
	<b>Net Cash Flows from (used in) operations</b>	<b>398.77</b>	<b>766.55</b>
	Dividend received	-	-
	Interest paid	-	-
	Interest received	-	-
	Income taxes paid (refund)	32.43	48.84
	Other inflows / (outflows) of cash	-	-
	<b>Net Cash Flows from (used in) Operating Activities</b>	<b>366.34</b>	<b>717.71</b>

<b>B</b>	<b>Cash flows from (used in) Investing Activities</b>		
	Cash flows from losing control of subsidiaries or other	-	-
	Cash flows used in obtaining control of subsidiaries or other businesses	-	-
	Other cash receipts from sales of equity or debt instruments of other entities	-	-
	Other cash payments to acquire equity or debt instruments of other entities	-	-
	Other cash receipts from sales of interests in joint ventures	-	-
	Other cash payments to acquire interests in joint ventures	-	-
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	-	-
	Cash payment for investment in partnership firm or association	-	-
	Proceeds from sales of tangible assets	-	3.89
	Purchase of tangible assets	(91.35)	(67.35)
	Proceeds from sales of intangible assets	-	-
	Purchase of intangible assets	-	-
	Cash advances and loans made to other parties	-	-
	Cash receipts from repayment of advances and loans made to other parties	-	-
	Dividends received	-	-
	Interest received	-	-
	Income taxes paid (refund)	-	-
	Other inflows (outflows) of cash	-	-
	<b>Net cash flows from (used in) Investing Activities</b>	<b>(91.35)</b>	<b>(63.46)</b>
<b>C</b>	<b>Cash flows from (used in) Financing Activities</b>		
	Proceeds from issuing shares	-	-
	Proceeds from Security Premium	-	-
	Proceeds from issuing other equity instruments	-	-
	Proceeds from issuing debentures, notes, bonds, etc	-	-
	Proceeds from borrowings	289.27	-
	Repayment of borrowings	(593.58)	(879.33)
	Dividend paid	-	-
	Interest paid	(102.31)	(291.15)
	Income taxes paid (refund)	-	-
	Other inflows (outflows) of cash	4.74	408.37
	<b>Net cash flows from (used in) Financing Activities</b>	<b>(401.88)</b>	<b>(762.11)</b>
<b>D</b>	<b>Net Increase / (Decrease) in Cash and Cash Equivalents</b>	<b>(126.89)</b>	<b>(107.86)</b>
	Cash & Cash Equivalents at the beginning of period	198.14	306.00
<b>E</b>	<b>Cash &amp; Cash Equivalents at the end of period</b>	<b>71.25</b>	<b>198.14</b>

For, Aashka Hospitals Limited

Bipinchandra D. Shah  
Chairman & Managing Director  
DIN: 00934108

Date: October 30, 2024  
Place: Gandhinagar